scholarly journals Para - And Intraurethral Penile Tumor - Like Condylomatosis

2018 ◽  
Vol 6 (1) ◽  
pp. 110-111
Author(s):  
Anastasiya Atanasova Chokoeva ◽  
Uwe Wollina ◽  
Torello Lotti ◽  
Georgi Konstantinov Maximov ◽  
Ilia Lozev ◽  
...  

Condyloma acuminata represents an epidermal manifestation, associated with the epidermotropic human papillomavirus (HPV). They have been reported as the most common sexually transmitted disease, with prevalence exceeding 50%, increased up to 4 times, within the last two decades, as the most common side of affection are the penis, vulva, vagina, cervix, perineum, and perianal area, with increased prevalence in young, sexually active individuals.  Increased attention should be focused on lesions, caused by types, with moderate (33, 35, 39, 40, 43, 45, 51-56, 58) or high risk potential (types 16, 18) for malignant transformation, leading to further development of cancers of anus, vagina, vulva and penis, as well as cancers of the head and neck . A provident of coexistence of many of these types in the same patient could be seen in approximately 10-15% of patients, as the lack of adequate information on the oncogenic potential of many other types complicated the treatment and the further outcome. Although the variety of treatment options, genital condylomata acuminata still show high recurrent rate to destructive topical regiments, because of the activation of the viruses at some point, which emphasise the importance of virus- eradication, instead only of the topical destruction of the lesions.  Despite decreasing the recurrent rate, the most important goal of immunisation is the reduction of the incidence of HPV-associated squamous cell carcinomas using either the quadrivalent (Silgard/Gardasil) or the bivalent (Cervarix) HPV (human papillomavirus) vaccine. We present a patient with periurethral condylomata acuminate, who refused performing of a biopsy for determining the virus type, as we want to emphasize the importance of the virus - treatment in all cases of genital warts, instead only of topical destruction of the lesions, not only because of the recurrence incidence rate, but also because of the well - known oncogenic potential of some HPV - types, as well as the unknown potential of various underestimated types, in contrast.

2008 ◽  
Vol 34 (1) ◽  
pp. 65-84 ◽  
Author(s):  
Tracy Solomon Dowling

Merck’s recently released vaccine, Gardasil, may revolutionize cervical cancer prevention. With the rate of detected cervical cancer cases and associated deaths rising rapidly, cervical cancer is a major public health concern. Infection with the human papillomavirus, a sexually transmitted disease, is a necessary cause of cervical cancer. Gardasil protects against two specific “high risk” strains of HPV, associated with about 70% of cervical cancer cases, and blocks infection by two other strains of HPV, responsible for 90% of genital warts cases. Proponents of Gardasil believe that vaccination of women between the ages of 12 and 26 can slow the spread of cervical cancer by eradicating the two major HPV strands associated with the cancer’s development.


2009 ◽  
Vol 7 (2) ◽  
pp. 129-138
Author(s):  
Victoria Barry ◽  
Shannon B. Myers ◽  
Amy E. Sgrenci ◽  
Megan Lavery ◽  
Deirdra Frum ◽  
...  

Recent strides have been made in developing vaccines to prevent contraction of the Human Papillomavirus (HPV), which is currently the most prevalent sexually transmitted disease in the United States. This study looked to investigate seven sexually relevant variables hypothesized to be related to a young woman's choice to receive the Gardasil® vaccine in order to prevent HPV contraction via a cross sectional survey. In a sample of 77 undergraduate women, we investigated the relationship between receipt of Gardasil® and the following variables: knowledge regarding HPV, relationship status, seeking gynecological services, having received an abnormal PAP smear, sexual activity status, number of sexual partners, and concern about contracting HPV. Logistical regression analysis and independent groups t-test revealed that none of these factors were related to actual receipt of the HPV vaccine in this sample. These results suggest the need for more research regarding potential practical barriers to HPV vaccination.


Sign in / Sign up

Export Citation Format

Share Document